TME Pharma NV (Euronext Growth Paris: ALTME), a biotechnology company specializing in the development of novel therapies for the treatment of cancer by targeting the tumor microenvironment (TME), announces that the US Food and Drug Administration (FDA) has granted Fast Track designation to NOX A12 (olaptesed pegol), its CXCL12 inhibitor, in combination with radiotherapy and bevacizumab, for use in the treatment of the recently diagnosed aggressive adult brain cancer glioblastoma , resistant to chemotherapy and presenting a measurable residual tumor post-surgery.
To receive all of the company’s financial communications in real time, please register directly by email to the following address: [email protected]